Shalby has announced its financial results for the quarter ending on December 31, 2022.
Consolidated performance highlights: Q3 FY2023 vs Q3 FY2022
- Consolidated revenues of Rs 2,067 million, growth of 25.1 per cent y-o-y
- Consolidated EBITDA of Rs 380 million, growth of 22.5 per cent y-o-y
- Consolidated profit after tax was Rs 153 million, growth of 18 per cent y-o-y
- Basic EPS of Rs 1.42 during the quarter, growth of 19 per cent y-o-y
- Occupied bed during the quarter were 544, growth of 6 per cent y-o-y
- In patient count (incl. day care) of 18,000, growth of 15 per cent y-o-y
- Total surgery count of 6,782, growth of 19.4 per cent y-o-y
- ARPOB during the quarter was 36,291, growth of 13 per cent y-o-y
Shanay Shah, President said, “I am happy to report that our hospital business continued to deliver consistent performance in all key operational and financial parameters with surgery count and In-patient count (Incl day care) grew by 19 per cent and 15 per cent Y-o-Y respectively in Q3 FY23. Hospital revenue and EBITDA also grew by 17.4 per cent and 23.5 per cent Y-o-Y with robust EBITDA margin of 21.5 per cent in Q3 FY23. ARPOB and ALOS were recorded at Rs 36,291 and 3.74 respectively in Q3 FY23 vis-à-vis Rs 32,049 and 4.02 in the same quarter of the previous year. Our core specialties such as Arthroplasty, Oncology, Cardiac Science, Orthopedic, Critical care & General Medicine, and Neurology contributed 85 per cent to the revenues respectively in Q3 FY23. International revenue continued to grow by 58 per cent y-o-y in Q3 FY23 from Q3 FY22 whereby majority of the patients came from East African countries. Homecare business showed a strong performance grew by 42 per cent y-o-y in Q3 FY23, from Q3 FY22. The Shalby Academy vertical also showed an encouraging response with 300+ students enrolled for various healthcare programs during Q3 FY23.Our realised return on capital employed from hospital business recorded at 16.3 per cent in 9M FY23 on annualised basis.”
- Advertisement -